Pages that link to "Q96171244"
Jump to navigation
Jump to search
The following pages link to Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 (Q96171244):
Displaying 10 items.
- Psychosocial Vulnerabilities to Upper Respiratory Infectious Illness: Implications for Susceptibility to Coronavirus Disease 2019 (COVID-19) (Q97518232) (← links)
- BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy (Q97520951) (← links)
- Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma (Q97537915) (← links)
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus (Q97540422) (← links)
- The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge (Q98778692) (← links)
- Immunopharmacology and Quantitative Analysis of Tyrosine Kinase Signaling (Q99546820) (← links)
- T cell responses and therapies against SARS-CoV-2 infection (Q99552640) (← links)
- Chemokine Regulation During Epidemic Coronavirus Infection (Q106555034) (← links)
- Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches (Q107404359) (← links)
- Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome (Q110013233) (← links)